Trimunocor Ltd Company Profile, Contacts & Intelligence

Trimunocor Ltd Overview

Developing ground-breaking solutions in the fight against neonatal chronic lung disease. Half of premature babies under 26 weeks develop neonatal chronic lung disease. This is a debilitating disease and there are no effective treatments to prevent it. These babies are deficient in the natural anti-inflammatory/anti-infective protein, surfactant protein D (SP-D). This protein is lacking in the current therapies. However, we have developed a novel way to produce the functional part of this natural defence protein. Having extensive pre-clinical efficacy data demonstrating the treatment of replacing this deficient protien, using an 'Aid for Start up' Innovate grant we are currently developing a GMC manufacturing procedure and preparing for clinical trials.

Headquarters

Hertfordshire, United Kingdom

Website

trimunocor.com

Industry

Biotechnology Research

Founded

2013

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Company Email

Available in AeroLeads

Trimunocor Ltd Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Compare Similar Companies to Trimunocor Ltd

Explore companies in related markets and compare their industry and employee estimates.